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Abstract
The Rift Valley fever virus is responsible for periodic, explosive epizootics throughout sub-Saharan Africa. The development
of therapeutics targeting this virus is difficult due to a limited understanding of the viral replicative cycle. Utilizing a virus-
like particle system, we have established roles for each of the viral structural components in assembly, release, and virus
infectivity. The envelope glycoprotein, Gn, was discovered to be necessary and sufficient for packaging of the genome,
nucleocapsid protein and the RNA-dependent RNA polymerase into virus particles. Additionally, packaging of the genome
was found to be necessary for the efficient release of particles, revealing a novel mechanism for the efficient generation of
infectious virus. Our results identify possible conserved targets for development of anti-phlebovirus therapies.
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Introduction
Rift Valley fever virus (RVFV) is an aerosol- and mosquito-
borne virus endemic to sub-Saharan Africa [1]. RVFV causes
periodic, explosive epizootics, affecting livestock and humans [1].
Sheep and cattle are particularly susceptible to the virus, with
abortion rates approaching 100% and high mortality rates among
young animals [2]. Most humans infected with RVFV have a flu-
like illness [1]. However, a small percentage of cases are more
severe and include manifestations such as hemorrhagic disease and
encephalitis [3,4,5]. Despite the severity of the disease to the
economy and human health, there are no USDA or FDA-
approved therapeutic or prophylactic treatments. A better
understanding of the RVFV replication cycle may lead to the
identification of novel therapeutic targets. In this study, we have
identified roles for each of the viral structural components in the
assembly and release of RVFV and have identified a potential
conserved target for therapeutic development.
RVFV is a segmented, negative-sense RNA virus belonging to
the family Bunyaviridae, genus Phlebovirus. The 12 kilobase genome
is comprised of three segments termed L, M and S, which encode
for the RNA-dependent RNA polymerase (RdRp), envelope
glycoproteins (Gn/Gc) and nucleocapsid protein (N), respectively
[1]. The S and M segments also encode nonstructural proteins
known as NSs and NSm, however these proteins are dispensable
for RVFV replication in cell culture [6,7,8]. Upon entry into host
cells, the encapsidated genome and RdRp are released into the
cytoplasm where transcription and replication of the viral genome
occurs [1]. RdRp acts as both transcriptase and replicase [9], but
requires N for both activities [10]. RdRp and N do not contain
signal peptides, and are presumably translated on cytoplasmic
ribosomes. The glycoproteins enter the secretory pathway as a
precursor polyprotein, which is cleaved by signal peptidase to yield
mature Gn and Gc [11]. Gn and Gc form a complex and localize
in steady-state to the Golgi apparatus, the site of virus assembly,
due to a localization signal on Gn [11,12,13]. It is not known how
the encapsidated genome and RdRp are recruited to the Golgi
apparatus for virus assembly or which viral components are
involved in the cellular release of virus.
Utilizing a Rift Valley fever virus-like particle (RVF-VLP)
system, we have determined that encapsidated genome acts as the
primary stimulus for RVFV release from the cell. The driving of
virus release by encapsidated genome is an elegant mechanism for
ensuring that infectious particles are the dominant specie released
from cells. We demonstrate that Gn is necessary and sufficient for
packaging of the RdRp and N. Furthermore, we show that distinct
regions of the Gn cytosolic tail are required for binding RdRp and
N. These data provide the most complete description of RVFV
assembly and release to date, and suggest novel targets of the
development of anti-phlebovirus drugs.
Materials and Methods
Plasmid Constructs
All plasmids were generated using standard molecular cloning
techniques and were confirmed by sequencing. The constructs
pTrRVFV-SDNSs::GFP, pN-Amp, pRdRp-Amp, pGn/Gc-Amp,
and pGnK48Stop-Amp have been described previously [6,12].
The minigenome, pSTrRVFV-SDNDNSs::hRLuc, was derived
from pTrRVFV-SDNSs::GFP by replacing the GFP gene with a
humanized renilla luciferase gene (RLuc), then deleting a 237
nucleotide SmaI fragment of the N gene. The expression
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open reading frames into pVAX1 (Invitrogen) using the HindIII/
EcoRI and BamHI/NotI sites, respectively. The open reading
frames from pGn/Gc-Amp and pGnK48Stop-Amp were cloned
into pVAX1 using BamHI and EcoRI sites, generating pGn/Gc,
pGc, pGn, and pGnK48. The expression plasmid, pGcW1, was
generated by site-directed mutagenesis of Trp1189 to a stop codon
in pGc, thus deleting the entire predicted cytoplasmic tail. Site-
directed mutagenesis of pRdRp generated the catalytic domain
RdRp mutant alleles pRdRp
cat1 and pRdRp
cat2, which were
mutated to Ala at residues Asp1134 and Ser1132, respectively.
Cells and virus
BSR-T7/5 cells were a generous gift of Dr. K. Conzelmann
(Max-von Pettenkofer-Institut, Munchen, Germany). The BSR-
T7/5 clonal cell line was generated through limiting dilution of the
BSR-T7 cells. The cells were grown in Dulbecco’s Modified Eagle
Medium (Invitrogen) supplemented with 10% fetal calf serum, and
1 mg/mL Geneticin. RVFV ZH548 MP12 vaccine strain was a
generous gift of Dr. R. Tesh (World Reference Center of
Emerging Viruses and Arboviruses).
Antibodies
Hybridomas that secrete neutralizing monoclonal antibodies
recognizing Gn and Gc (R1-4D4-1-1 and R5-3G2-1A) were a
generous gift of Dr. G. Ludwig (USAMRIID). Polyclonal antibodies
that were generated against RVFV in mice were a generous gift of
Dr. P. Rollin (CDC). The N-terminal 150 amino acids of the RdRp
and full-length N were expressed with N-terminal histidine tags and
purified under denaturing conditions on Ni-NTA agarose columns
(Qiagen Inc.). RdRp and N polyclonal antibodies were generated in
rabbits using these purified proteins as antigens (Harlan Laborato-
ries). Monoclonal antibodies recognizing GS-28 and b-COP were
purchased from Transduction Labs and ABR, respectively.
Horseradish peroxidase-conjugated secondary antibodies, goat
anti-rabbit and goat anti-mouse, were acquired from Amersham
and MP Biomedical, respectively. AlexaFluor 488-labelled goat
anti-rabbit and AlexaFluor 594-labelled goat anti-mouse were
purchased from Invitrogen.
Virus-like particle production
BSR-T7/5 cells were plated at a density of 1.2610
6 cells/plate.
After 24 h, cells were transfected using 2 mL TransIT LT1 (Mirus
Corporation)/mg DNA and plasmids in the ratio 6.0 mg mini-
genome: 6.0 mg pN: 6.0 mg pRdRp: 3.0 mg pGn: 3.0 mg pGc/
10 cm plate. The amount of plasmid transfected was scaled to the
number of cells. The media was changed 24 h post-transfection.
After 48 h post-transfection, the RVF-VLPs were harvested from
the media, then clarified by low-speed centrifugation (300 rcf for
10 min at 4uC) to remove cellular debris. The transfected cells
were analyzed by RLuc assay (Promega) in order to verify that
RLuc activity levels were similar across experimental attempts.
Virus-like particle infections
BSR-T7/5 cells were used as target cells for RVF-VLP
infections. These cells were either not transfected or transfected
using 2 mL TransIT LT1 (Mirus Corporation)/mg DNA and
0.25 mg pRdRp and 0.25 mg pN per well of a 24-well plate.
Transfected cells were infected with RVF-VLPs 24 h post-
transfection. RVF-VLP-infected target cells were harvested 24 h
post-infection and were analyzed for RLuc activity. The raw
luciferase units (RLU)/mL of RVF-VLPs added to target cells was
calculated for three or more separate experiments. The log of the
average RLU/mL was calculated for analysis by Independent T-
Test (SPSS Statistical Package 14.0), and compared to the negative
control (-Gn/-Gc).
High-speed ultracentrifugation of RVF-VLPs
Clarified samples containing RVF-VLPs were subjected to high-
speed ultracentrifugation at 82,000 g for 16 h using either a SW-
28 or SW50.1 rotor, depending on sample size. The supernatant
was decanted and the pellet was resuspended in Laemmli sample
buffer, citrate buffer (10 mM citrate, pH 6.4) or 0.1 M Sorensen
phosphate buffer, depending on experiment.
Immune precipitation of RVF-VLPs
Mouse monoclonal antibodies recognizing either Gn (R1-4D4-
1-1) or Gc (R5-3G2-1A) were conjugated to Dynal magnetic beads
(Invitrogen) by incubating overnight at 4uC. The antibody-coated
beads were incubated overnight at 4uC with RVFV or RVF-VLPs,
then washed with Wash Buffer (10 mM Tris, 5 mM MgCl2, and
100 mM NaCl, pH 7.8), and resuspended in 1X Laemmli sample
buffer for analysis by immunoblot. To prevent variation between
conditions, generation of RVF-VLPs, immune precipitation, and
immunoblotting were performed for all conditions at the same
time. The representative immunoblots in the figures are from a
single immunoblot split into the different figures. Therefore, each
figure displays the same positive (WT) and negative (-Gn/-Gc)
controls for comparison. The extensive experiments were
performed multiple times, but only an immunoblot from a single
experiment is shown.
Transmission electron microscopy
RVFV and RVF-VLPs were pelleted by high-speed ultracen-
trifugation and resuspended in 0.1 M Sorensen phosphate buffer,
and distributed onto a carbon-coated grid. The particles were
fixed with 2.5% glutaraldehyde in Sorensen phosphate buffer and
negative stained with aqueous 1% uranyl acetate, which was
performed by the Microscopy Imaging Laboratory (University of
Michigan). The particles were viewed on a Philips CM100
transmission electron microscope at 60 KV. Images were recorded
digitally using a Hamamatsu ORCA-HR digital camera system,
which was operated using AMT software (Advanced Microscopy
Techniques Corp., Danvers, MA). The sizes of RVFV and RVF-
VLPs were measured using ImageJ software (NIH). The diameter
of particles was measured outer membrane to outer membrane for
a minimum of 10 particles per condition.
RT-PCR detection of genomic RNA in RVF-VLPs
RVF-VLPs were generated as described above, except that at
24 h the media was replaced with fresh media that contained
90 U/mL Benzonase (Novagen). At 48 h RVF-VLPs were
harvested from 4 mL of media by high-speed ultracentrifuation.
The pelleted material was resuspended in PBS and the RNA
isolated by extraction with phenol/chloroform followed by ethanol
precipitation. The pellet was resuspended in 20 mL citrate buffer.
cDNA was generated from 4 mL of RNA using M-MuLV reverse
transcriptase (New England BioLabs) and primers that recognize
the 59 and 39 termini of the genomic RNA (ACACAAAGCTCC-
CTAGAGATAC and AAGCACTAGGGGGTCTTTGTGT).
The cDNA was amplified (29 cycles) using Phusion polymerase
(New England BioLabs) and primers that anneal within N
(CATGAGAAGAGGAGAGAATTCT) and RLUC (ACGAT-
GGCCTTGATCTTGTC). The expected RT-PCR product size
is 773 nucleotides and includes the intergenic region of the
genome.
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Gn and N
BSR-T7/5 cells were grown in 12-well plates and transfected
with the plasmids indicated in the figure. The amount of DNA
transfected was held constant by addition of empty vector
(pVAX1) when necessary. At 48 h post-transfection the media
was removed and the cells were washed with PBS. The cells were
then exposed to 250 mM Dithiobis[succinimidyl] propionate
(Pierce) in PBS for 30 min at room temperature. The cross-linking
solution was removed at the end of the incubation and replaced
with 400 mL of 5X RIPA buffer (250 mM Tris-HCl, pH 7.5,
0.75 M NaCl, 5 mM EDTA, 5% Triton X-100, 5% sodium
deoxycholate, 1% SDS). The samples were then diluted to 1X
RIPA by the addition of water. Insoluble material was removed by
centrifugation at 16,000 g for 5 min. Mouse monoclonal antibod-
ies recognizing Gn (R1-4D4-1-1) were conjugated to protein G
agarose (Pierce) by incubating overnight at 4uC. The samples were
incubated with the antibody-coated beads for 1 h at 4uC then
washed three times with 1X RIPA buffer. The final wash was
removed and the beads were resuspended in Laemmli sample
buffer with 10% b-mercaptoethanol. The samples were analyzed
by immunoblot using rabbit anti-Gn and anti-N antibodies.
Immunofluorescence
BSR-T7/5 cells were plated on glass coverslips at
5.0610
4 cells/well of a 24-well plate. After 24 h, the cells were
transfected using 2 mL TransIT/mg DNA. The cells were fixed
24 h post-transfection with 4% paraformaldehyde in phosphate-
buffered saline (PBS), then permeabilized using 0.2% Triton X-
100 in PBS with 1% bovine serum albumin. Mouse monoclonal
antibodies recognizing Gn and Gc and rabbit polyclonal
antibodies recognizing the RdRp and N were used as primary
antibodies, while AlexaFluor488-labelled goat anti-rabbit and
AlexaFluor 594-labelled goat anti-mouse were used as secondary
antibodies (Invitrogen). Fluorescence visualization and imaging
were performed using an Olympus 51-X fluorescent light
microscope at the Microscopy Imaging Laboratory (University of
Michigan). Cells with clear signals for both red (594 nm) and green
channels (488 nm) were counted, then, analyzed for co-localiza-
tion. Positive co-localization was defined as the RdRp exhibiting a
focus of intense staining corresponding to the Golgi/glycoprotein
signal. Diffuse cytoplasmic staining and small puncta in the
cytoplasm were not counted for positive co-localization.
Efficiency of RVF-VLP Cellular Release
Efficiency of cellular release was determined through quantita-
tion of Gn/Gc levels in the cell lysates and within the RVF-VLPs.
RVF-VLPs were purified through high-speed ultracentrifugation
or immune precipitation. Both methods generated similar results
for the release efficiencies, therefore immunoblots from both types
of purification were combined to calculate the average release
efficiencies with standard deviation and to perform the statistics.
Immunoblots were scanned on a PhosphoImager and analyzed
using ImageQuant 5.2 (Molecular Dynamics) to determine the
signal intensity (volume). Glycoprotein signal volume from the cell
lysates was divided by background volume to attain the
normalized glycoprotein expression levels in the cell lysates. The
glycoprotein signal volume for RVF-VLPs was divided by the
normalized glycoprotein signal from the corresponding cell lysate.
Normalizing the glycoprotein signal for RVF-VLPs had little to no
effect on the calculated release efficiencies for conditions lacking
genome, N, RdRp or with the RdRp
cat1 allele since glycoprotein
expression levels were similar across these conditions. However,
the immunoblot signals for GnK48 and GcW1 alleles were lower
(,25–50%, depending on experiment) than for their wild-type
counterparts making it necessary to normalize for input. Release
efficiencies were calculated as a percentage of the WT condition.
Statistics were performed for the comparison of glycoprotein
expression levels from experiments performed in triplicate using
One Sample T-Tests (SPSS Statistical Package 14.0).
Results
RVFV and RVF-VLPs have similar morphology and protein
content
A T7 RNA polymerase-dependent system was used for the
efficient generation of RVF-VLPs [14]. Briefly, RVF-VLPs were
produced by expression of an S segment-based minigenome
(pSTrRVFV-SDNDNSs::hRLuc), N, RdRp, Gn, and Gc in BSR-
T7/5 cells. The minigenome contains a humanized renilla
luciferase (RLuc) gene in place of the NSs ORF and an internal
deletion in the N gene that prevents expression of N [14]. RVFV
and RVF-VLPs were harvested by ultracentrifugation and
analyzed for particle morphology by transmission electron (Fig. 1)
and protein composition by immunoblot (Fig. 2). RVFV and the
RVF-VLPs exhibited similar size and morphology by transmission
electron microscopy. All of the viral proteins were detected in the
cell lysates (C) and pelleted material (P) for RVFV and the RVF-
VLPs (Fig. 2). Similar ratios of glycoprotein to N were found in
RVFV and RVF-VLPs (Fig. 2), although the glycoprotein to
RdRp ratio was higher for RVF-VLPs (2.3 versus 6.0). The latter
result was not surprising given that much more RdRp was found
in transfected versus infected cells. There appears to be some
differences with respect to the species of glycoproteins present in
RVFV and RVF-VLP preparations in both the cell lysate and
pelleted material (Fig. 2). These differences may reflect the fact
that our glycoprotein expression construct does not include the
NSm region of the M segment, a region that is dispensable for
virus maturation, replication and infection [6,8]. The envelope
glycoproteins are synthesized as an N-terminal nested set that
yields at least two mature glycoproteins containing the NSm
region [11,15,16]. In addition to similarities in particle morphol-
ogy and protein composition, RVFV and the RVF-VLPs are
antigenically indistinguishable and respond similarly to inhibitor
compounds [14]. All of our data suggest the RVF-VLPs function
similar to virus and will be useful in dissecting steps of the RVFV
replication cycle.
Gn recruits RdRp from the cytoplasm
Replication and transcription of the viral genome by RdRp
occurs in the cytoplasm and assembly of virus particles takes place
at the Golgi apparatus [1]. We investigated the localization of
RdRp in the absence of other viral proteins. It is believed that all
bunyavirus RdRp are translated on free ribosomes in the
cytoplasm [1], however the localization of wild-type RVFV RdRp
had not been determined previously. When expressed in the
absence of other viral proteins, RdRp was found distributed
diffusely throughout the cytoplasm and did not co-localize with the
resident Golgi protein, GS-28 (Fig. 3A). By contrast, Gn co-
localized with the resident Golgi protein b-COP (Fig. 3A), in
agreement with previously published reports [12]. The envelope
glycoproteins are presumably responsible for recruitment of RdRp
to the site of virus assembly, the Golgi apparatus. We tested this
hypothesis by co-expressing RdRp with the glycoproteins then
determining if the cytoplasmic localization of RdRp was altered.
Gn and Gc are integral membrane proteins that are expressed as a
polyprotein precursor [11,15]. The polyprotein is cleaved by signal
RVFV Release Requires Genome
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mature Gn retains the signal peptide of Gc [11,16]. Gn and Gc
form a heteromeric complex that localizes in steady-state to the
Golgi apparatus [11,12]. Expression of the glycoproteins along
with RdRp resulted in localization of RdRp to a focus of intense
staining co-localizing with Gn (Fig. 3B), indicating that one or both
glycoproteins is necessary for recruitment of RdRp. When Gc was
co-expressed with RdRp, the cytoplasmic localization of RdRp
was not altered (Fig. 3B). By contrast, co-expression of Gn was
sufficient to alter the localization of RdRp (Fig. 3B). A portion of
the RdRp co-localized with Gn in 57% of cells, indicating that Gn
is necessary and sufficient for the recruitment of RdRp.
The domain within Gn that is responsible for the recruitment of
RdRp was identified using a Gn allele that lacks the last 40 amino
acids of the cytoplasmic tail and the Gc signal peptide (GnK48).
Although GnK48 localizes properly to the Golgi apparatus [12], it
was unable to recruit RdRp (Fig. 3B). Therefore, the last 40 amino
acids of the Gn cytoplasmic tail and/or the Gc signal peptide is
necessary for the recruitment of RdRp.
Generation of infectious RVF-VLPs requires packaging of
a catalytically active RdRp
Packaging of RdRp into virus particles is necessary for RVFV to
produce progeny in infected cells. However, it is not known
whether RdRp is necessary for efficient production of virus
particles. This question was addressed by determining if RVF-
VLPs could be produced when RdRp was absent or when the Gn
mutant that fails to recruit RdRp (GnK48) was expressed. BSR-
T7/5 cells were transfected with minigenome, pN, pRdRp, pGn,
and pGc or one or more of the components were replaced with an
equivalent amount of empty vector or pGnK48. RVF-VLPs were
visualized by transmission electron microscopy and immune
precipitated RVF-VLPs were analyzed for protein composition
by immunoblot. Only WT, –RdRp and GnK48 conditions
generated quantities of RVF-VLPs that were sufficient for accurate
estimates of RVF-VLP size. RVF-VLPs made in the absence of
RdRp or expressing GnK48 did not display gross differences in
morphology as compared to WT (Fig. 1), indicating that RdRp is
not required for generation of particles. As expected, RdRp signal
was present in RVF-VLPs when all components were expressed
(WT) and absent when RdRp was not expressed (-RdRp) (Fig. 4A).
When the GnK48 allele was expressed, almost no RdRp was
found in RVF-VLPs (Fig. 4A). This result is in agreement with the
co-expression results (Fig. 3B) and confirms that GnK48 is unable
to recruit RdRp. Although RdRp is not required for RVF-VLP
production, particles that lack RdRp (-RdRp and GnK48) are
,20% larger than WT and display greater size variability (Fig. 1),
indicating that loss of RdRp is not innocuous. Additionally, there
appears to be some subtle differences in glycoprotein species found
within cells, and possibly within RVF-VLPs, when RdRp is absent
(Fig. 4A). We do not know the molecular nature of these
differences, however since RdRp and Gn interact, it would not
be surprising if RdRp altered the trafficking and/or post-
translational modification of Gn. Glycoprotein to N ratios for
WT and no RdRp (-RdRp) conditions were similar, indicating
that loss of RdRp did not adversely impact packaging of N. We
then determined whether a catalytically active RdRp is required
for interaction with Gn. Neither catalytic domain RdRp mutant
has measurable catalytic activity (data not shown). Similar to wild
type RdRp, RdRp
cat1 and RdRp
cat2 co-localized with Gn,
indicating that catalytic activity is not required for this interaction
(Fig. 4B). These results are supported by our immunoblot results
showing that RdRp
cat1 is packaged into RVF-VLPs (Fig. 4A).
Figure 1. RVFV and RVF-VLPs have similar morphology. RVFV and RVF-VLPs were harvested by ultracentrifugation and analyzed by
transmission electron microscopy with negative staining. The particle sizes were measured, and the values listed are the mean sizes of particles with
standard deviation.
doi:10.1371/journal.pone.0018070.g001
Figure 2. RVFV and RVF-VLPs have similar protein composi-
tion. Lysates from transfected (RVF-VLP) or RVFV-infected cells (C), and
pelleted particles (P) were analyzed by immunoblot. The numbers
below the immunoblots indicate the ratio of glycoprotein to N signal.
doi:10.1371/journal.pone.0018070.g002
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PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e18070Figure 3. Gn recruits RdRp. A. BSR-T7/5 cells were transfected with pRdRp or pGn, and the proteins were visualized with anti-RdRp and anti-Gn,
respectively (green channel). Cellular resident Golgi apparatus proteins, GS-28 or b-COP were also labeled (red channel). Percentage of cells
displaying co-localization of viral proteins with resident Golgi proteins is indicated with the number of cells counted in parentheses. B. BSR-T7/5 cells
were transfected with pRdRp and either pGn/pGc, pGc, pGn, or pGnK48. Cells were incubated with anti-RdRp (green channel) and anti-Gn or anti-Gc
(red channel), and then analyzed by immunofluorescence microscopy. Percentage of cells displaying co-localization of RdRp with Gn or Gc is
indicated with the number of cells counted in parentheses.
doi:10.1371/journal.pone.0018070.g003
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expressed in target cells (trans expression) could rescue infectivity
of RdRp-deficient or RdRp
cat1 RVF-VLPs. Wild-type RVF-VLPs
were capable of infecting untransfected target cells and had RLuc
activity that was 700-fold above background (Table 1). Tran-
scription of the RLuc reporter in target cells could be enhanced
through expression of a catalytically active RdRp in trans,
increasing the RLuc signal to 4,000-fold background levels
(Table 1). Expression of RdRp
cat1 in target cells did not enhance
RLuc signal as compared to untransfected target cells (Table 1),
indicating that the observed signal enhancement by wild-type
RdRp is due to catalytic activity and not cooperativity. By
contrast, RVF-VLPs packaging RdRp
cat1 or RVF-VLPs lacking
the RdRp (-RdRp) could not be complemented in trans with an
active RdRp (Table 1). Wild-type RVF-VLPs were the only
RVF-VLPs to generate a significant RLuc signal as compared to
background (-Gn/-Gc) (Table 1). These results indicate that
catalytically active RdRp must be packaged in the RVF-VLP in
Figure 4. Packaged, catalytically active RdRp is necessary for an early event in the replicative cycle. A. BSR-T7/5 cells were transfected
with genome and all of the structural proteins (WT), or one or more of the components was replaced with an equivalent amount of empty vector (-
Gn/Gc and –RdRp) or with plasmids expressing mutant alleles of Gn or RdRp (GnK48 or pRdRp
cat1). Transfected cells were analyzed for protein
expression by immunoblot. RVF-VLPs were immune precipitated from the clarified media from transfected cells and analyzed by immunoblot. The
numbers below the immunoblots indicate the ratio of glycoprotein to N signal. B. BSR-T7/5 cells were transfected with pGn and either pRdRp or
RdRp catalytic domain mutants, pRdRp
cat1 or pRdRp
cat2. Cells were incubated with anti-Gn (red channel) and anti-RdRp (green channel), and then
analyzed by immunofluorescence microscopy. Percentage of cells displaying co-localization of RdRp alleles with Gn is indicated with the number of
cells counted in parentheses.
doi:10.1371/journal.pone.0018070.g004
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(Table 1).
N is packaged into virions by Gn
After transcription and replication of the viral genome in the
cytoplasm, we hypothesized that encapsidated genome and RdRp
were recruited as a complex to the Golgi apparatus for assembly
through interaction between RdRp and Gn. However, we
discovered that N could be packaged into RVF-VLPs lacking
RdRp (Fig. 4A, -RdRp and GnK48). This result indicates that N
and RdRp can be packaged independently. Phlebovirus N
localizes to the cytoplasm when expressed alone (data not shown),
similar to N of tomato spotted wilt virus (Tospovirus genus) [17] and
La Crosse virus (Orthobunyavirus genus) [18], but in contrast to
Hantaan and Black Creek Canal viruses N (Hantavirus genus)
[19,20]. Phlebovirus N presumably interact with one or both of
the envelope glycoproteins in order to be assembled into virions.
The GnK48 allele was able to package N (Fig. 4A), which indicates
that the last 40 amino acids of the 70 amino acid Gn cytoplasmic
tail and the Gc signal peptide are not required for packaging of N.
Accordingly, Gc and/or the first 30 amino acids of the Gn
cytoplasmic tail appear necessary for its packaging. To determine
whether Gn or Gc is involved in N packaging, we transfected cells
with all viral components or equivalent amounts of plasmid
encoding the GcW1 allele or empty vector. GcW1 has a
premature stop codon at Trp1189, which deletes the predicted
Gc cytoplasmic domain in its entirety. Particles lacking Gn or Gc,
or containing GcW1, were analyzed for morphology and protein
content. Only WT and GcW1 produced particles efficiently, and
thus particle sizes were only measured for these two conditions
(Fig. 1). Deletion of the cytoplasmic tail of Gc (GcW1) had no
effect on average particle size or morphology as compared to WT
RVF-VLPs, however there was more size variation (Fig. 1). The
level of glycoproteins expressed in transfected cells varied by
experimental condition (Fig. 5A). Co-expression of full-length Gn
and Gc was required for high-level expression of each glycopro-
tein. Previous studies with the Bunyamwera virus (Orthobunyavirus
genus) identified a chaperone-like role for Gn in the folding of Gc
and a requirement for the Gc ectodomain for efficient Golgi
trafficking of Gn [21,22]. Therefore, finding reduced levels of Gc
and Gn when either was expressed alone was not surprising. The
average glycoprotein signal within RVF-VLPs generated with Gn
or Gc alone was near background levels (Fig. 5A). Interestingly, N
was still packaged into RVF-VLPs that lack Gc (Fig. 5A). No N
was found in RVF-VLPs that lacked Gn (Fig. 5A), however since
Gc levels are at background it is not possible to interpret this result.
When Gn was expressed with GcW1, both N and RdRp were
packaged into RVF-VLPs. The ratio of glycoprotein to N for
GcW1 and WT conditions was similar, supporting the view that
the cytosolic tail of Gc is dispensable for packaging of N.
Consistent with the immunoblot results (Fig. 5A), GcW1 RVF-
VLPs were infectious and yielded RLuc activity that was
significantly above background levels in target cells complemented
in trans with active RdRp and N (Table 2).
We then investigated whether Gn and N interaction is
modulated by genome or RdRp. BSR-T7/5 cells were transfected
with minigenome, pN, pRdRp, pGn, or one or more of the
components were replaced with an equivalent amount of empty
vector or pGnK48. At 48 h post-transfection, cellular proteins
were cross-linked with a thiol cleavable cross-linker (Dithiobis[-
succinimidyl] propionate), then Gn containing complexes were
immune precipitated with monoclonal anti-Gn antibodies. The
cross-linker was cleaved with b-mercaptoethanol and Gn and N
were analyzed by immunoblot (Fig. 5B). Presence of the RdRp in
these complexes was also analyzed, however the RdRp signal in
our positive control was not sufficient for reliable interpretation of
the results (data not shown). Gn-N interaction was independent of
RdRp (Fig. 5B, compare lanes 5 and 7), consistent with our ability
to form RVF-VLPs in the absence of RdRp (Fig. 1 and Table 3).
We were able to pull down N with Gn whether or not genome was
present (Fig. 5B, compare lanes 4 with 7). The GnK48 mutant is
also able to interact with N (Fig. 5B, lanes 10-12), indicating that
sequence required for N recruitment is within the first 30 amino
acids of the Gn cytosolic tail. These results are in agreement with
the results for RVF-VLPs generated with GnK48 (Fig. 4A), in that
GnK48 can bind N but fails to bind RdRp. While genomic RNA
is not required for Gn-N interaction (Fig. 5B, compare lanes 4 and
5), the interaction may still be RNA-dependent, since N has been
shown to be a non-specific single-stranded RNA binding protein
[23]. In the case of bacterially expressed N, ,90% is bound to
RNA [23] and we expect that the same is true of N expressed in
mammalian cells.
Genome triggers virus release
Gn can package both RdRp and N independently into RVF-
VLPs. Therefore, we investigated the individual roles of each of
these viral components in the release of RVF-VLPs from cells.
The minimal set of viral components necessary for the efficient
cellular release of RVF-VLPs was determined by transfection of
cells with minigenome, pN, pRdRp, pGn, and pGc, or with one
or more of the expression plasmids replaced by an equivalent
amount of empty vector. The RVF-VLPs were visualized by
transmission electron microscopy, immune precipitated RVF-
VLPs were analyzed for protein content by immunoblot, and




Log (RLU/mL) Std. Dev.
Average
Log (RLU/mL) Std. Dev.
Average
Log (RLU/mL) Std. Dev.
WT 6.61* 0.782 6.51* 1.10 8.15* 0.471
-Gn/-Gc 3.76 0.296 3.42 0.325 4.47 0.515
-RdRp n.d. 3.53 0.319 4.60 1.00
GnK48 n.d. 3.56 0.317 4.78 0.484
RdRp
cat1 n.d. 3.60 0.231 4.22 0.815
*Values are significantly different from -Gn/-Gc, p,0.005.
n.d.; not determined.
doi:10.1371/journal.pone.0018070.t001
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target cells. When wild-type viral proteins and genome were
expressed, RVF-VLPs were released from the cell and all viral
proteins could be visualized (Fig. 6). No particles were visualized
by electron microscopy when the genome, N, and RdRp, which
form the viral ribonucleoprotein complex, were expressed
without the envelope glycoproteins (-Gn/-Gc) and there was no
expression of the RLuc reporter above background levels
(-genome; no luciferase gene) in target cells (Table 4). Our results
corroborate the results of previous findings that ribonucleoprotein
complexes are not released from the cell in the absence of
glycoproteins [24].
We next determined which viral components are necessary for
efficient RVF-VLP release. For the purpose of this analysis we
equated RVF-VLP release with Gn/Gc signal on immunoblots of
isolated RVF-VLPs. Gn/Gc expression levels were measured and
normalized to expression levels in transfected cells. The experi-
mental condition that included all structural proteins and genome
(WT) was designated as 100% release efficiency and the condition
in which both envelope glycoproteins were omitted from the
transfection (-Gn/Gc) was considered background (Fig. 6 and
Table 3). The samples lacking N or the genome exhibited average
release efficiencies of only 15.6 and 18.1%, respectively (Table 3).
These efficiencies were similar to when the entire ribonucleopro-
Figure 5. Gn packages N. A. BSR-T7/5 cells were transfected with genome and all of the structural proteins (WT), or one or more of the
components was replaced with an equivalent amount of empty vector, (-Gn/-Gc, -Gn, or -Gc) or a plasmid expressing an allele of Gc that lacks the
entire cytoplasmic tail (GcW1). Transfected cells were analyzed for protein expression by immunoblot. RVF-VLPs were immune precipitated from the
clarified media from transfected cells and analyzed by immunoblot. The numbers below the immunoblots indicate the ratio of glycoprotein to N
signal. B. BSR-T7/5 cells were transfected with the indicated plasmids and proteins were cross-linked at 48 h post-transfection. Mouse monoclonal
anti-Gn antibodies were used to immune-precipitate Gn containing complexes. The cross-links were cleaved and then Gn-containing complexes were
identified by immunoblot using rabbit anti-Gn or rabbit anti-N antibodies.
doi:10.1371/journal.pone.0018070.g005
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demonstrate that efficient release requires both N and the genome,
presumably in the form of encapsidated genome. Conversely, the
absence of RdRp did not adversely affect the efficiency of release
of the glycoproteins or the packaging of N (Fig. 6 and Table 3),
indicating that RdRp does not play a critical role in viral budding
or release. Particles can be generated at low levels when either Gn
or Gc is absent, however the amount of glycoproteins released was
at or below the limit of detection by immunoblot. Release
efficiencies were decreased ,2-fold when either GnK48 or GcW1
(Table 3) was expressed, however this decrease was only significant
for GnK48. Since N is packaged under both conditions (Fig. 4A
and 5A), the cytoplasmic tails of these glycoproteins may perform
additional functions in the release process.
Genome is packaged into RVF-VLPs that lack RdRp
The presence of genome in RVF-VLPs can be inferred from
RLuc activity in infected cells. However, many of the experimental
conditions used in this study (-N, -Gn, -Gc, -RdRp and GnK48)
do not produce RLuc in target cells at levels significantly different
from a negative control (-Gn/Gc) (Table 1). Since RVFV can
package both sense and anti-sense genomic RNA [25,26], the
requisite packaging signals must be present on both senses of
genomic RNA. Therefore cells used to make RVF-VLPs in the
absence of replication (e.g. –N and –RdRp) contain genomic RNA
(synthesized by T7 RNA polymerase) that is competent for
packaging. The presence or absence of both senses of genomic
RNA in RVF-VLPs was assayed by RT-PCR. BSR-T7/5 cells
were transfected with minigenome, pN, pRdRp, pGn, pGc or one
or more of the components were replaced with an equivalent
amount of empty vector, pGnK48 or pGcW1. At 24 h the media
was replaced with fresh media containing benzonase, a nuclease
that degrades RNA and DNA. At 48 h RVF-VLPs were harvested
and 10% of each sample was passaged onto target cells. At 24 h
post-infection the cells were analyzed for RLuc activity (Table 5).
The addition of benzonase to the samples substantially reduced
the background of our RVF-VLP infectivity assay (compare
Tables 1 and 5), suggesting that carry-over plasmid and/or RNA
released from dying cells is contributing to the background
observed in earlier experiments (Tables 1–3). RVF-VLPs were
isolated from the remaining sample by ultracentrifugation and
then RNA was extracted. The extracted RNA was then subjected
to RT-PCR using primers that flank the intergenic region and are
expected to generate a 773-nucleotide product. The S segment is
ambisense and produces two mRNAs, both of which lack the
intergenic region [27,28]. Therefore, only genomic RNA (either
genome or anti-genome sense) can be amplified using our primer
set. We obtained an RT-PCR product of the expected size when
all viral components were co-expressed (Fig. 7, lane 1) but not
when either genome or both glycoproteins were omitted (Fig. 7,
lanes 2 and 5). These results were in agreement with our RLuc
activity assay (Table 1) that indicates genomic RNA is delivered to
target cells when all viral components are co-expressed (WT) but
not when the glycoproteins are absent (-Gn/Gc). When RdRp is
absent or GnK48 is expressed, RdRp is not found in RVF-VLPs
(Fig. 4A), however we obtain a RT-PCR product of the
appropriate size (Fig. 7, lanes 4 and 6), demonstrating that
genome is packaged. Our immunoblot analysis of immune
precipitated RVF-VLPs (Fig. 4A and 5A), cross-linking (Fig. 5B)
and immunofluorescence (Fig. 3B) results show that Gn contains
the sequences required for RdRp and N recruitment. Although
very few RVF-VLPs are produced when Gn or Gc are absent, we
found that genomic RNA was present in samples that lack Gc or
express the GcW1 allele (Fig. 7, lanes 8–9) but absent when Gn is
not expressed (Fig. 7, lane 7), consistent with our results
demonstrating that the Gc cytosolic tail is not required for the
generation of infectious particles. Surprisingly, we found that
genome was present in samples that lack N (Fig. 7, lane 3)
indicating that there may be a binding site for genomic RNA on
one of the envelope glycoproteins. Since N can bind RNA non-
specifically, this result may explain the specificity for genomic
RNA in promoting virus release.
Discussion
Efficient release of RVFV virions requires both the genomic
RNA and N, presumably in the form of encapsidated genome. N is
a non-specific single-stranded RNA binding protein that undoubt-
edly binds cellular RNA in the absence of genome [23]. However,
genomic RNA is required for efficient release of virus. The
requirement for genomic RNA is especially intriguing since it
indicates that the genome is not merely a passenger within the
virion, but actively participates in release of virus particles. The
termini of the genomic segments are complementary and are
expected to form a dsRNA structure that contains the sequences
necessary for packaging and the promoters for transcription and
replication [29]. We hypothesize that the packaging signal is
recognized by one of the glycoproteins, most likely Gn (Fig. 8).
Viral genomes have not been implicated in stimulating the
budding and/or release of any negative or positive-sense RNA
virus prior to this report.











*Values are significantly different from -Gn/-Gc, p,0.01.
doi:10.1371/journal.pone.0018070.t002
Table 3. Encapsidated genome required for efficient cellular
release.













*Values are significantly different from WT RVF-VLP release efficiency, p,0.005.
{Value is significantly different from WT RVF-VLPs release efficiency, p,0.05.
DYields were below the limit of detection.
{Insufficient number of replicates for std. dev. and p-value calculations.
doi:10.1371/journal.pone.0018070.t003
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encapsidated genome acts as the stimulus for virion formation. It
is thus reasonable to expect most virus particles to be infectious.
Many enveloped RNA viruses yield particle-to-plaque-forming
unit (pfu) ratios in the tens or hundreds [30,31,32,33], however
studies with Bunyamwera virus (Orthobunyavirus genus) determined
that the particle-to-pfu ratio approaches one [34]. We propose
that the interactions between the encapsidated genomic segments
and multiple Gn cause a change in membrane curvature that leads
to virus particle budding into the Golgi lumen (Fig. 8). The virus
buds when the critical quantity of genome is bound, presumably
corresponding to at least one copy each of S, M and L segments. It
remains to be seen if the segments are specifically or randomly
packaged.
Previous studies with the positive-sense RNA viruses, poliovirus
(Picornaviridae family) and Flock house virus (Nodaviridae family)
found that only actively replicating genomes were recruited for
virus assembly [35,36,37]. For poliovirus, it is hypothesized that
translation is coupled to replication of the genome and assembly of
the virus, so that only genomes that encode functional proteins are
replicated and packaged [35]. For the Flock house virus, it is
hypothesized that the replicating and non-replicating RNA
genomes segregate to distinct sub-cellular locations, allowing for
packaging of only the replicating RNA [37]. In contrast to
poliovirus and Flock house virus, RVFV can package replicating
or non-replicating ribonucleoprotein complexes. In fact, RVF-
VLPs produced in the absence of RdRp contain genome and are
released as efficiently as WT RVF-VLPs.
Our results support studies performed by Liu et. al. [38] using
a baculovirus expression system for generation of RVF-VLPs in
insect cells. They found that particles could be generated
through expression of Gn and/or Gc with N. Similarly, we
could not identify any particles by electron microscopy unless N
and Gn or Gc were co-expressed. Based on their ability to
visualize particles, Liu et. al. concluded that only N and the
envelope glycoproteins were required for generation of particles,
however efficiency of release could not be determined using their
methods [38]. We observed particles that lacked genome,
however RVF-VLP release was only efficient when genome
was present (Table 3).
Most RNA viruses require a matrix protein for the pack-
aging of the ribonucleoprotein complexes and release of viral
particles [1,39,40,41,42,43,44,45,46,47,48,49,50,51,52], however
viruses of the Bunyaviridae family do not encode a matrix
protein. Based on our results, the Gn cytoplasmic tail appears to
function in place of matrix and recruits RdRp, N and possibly,
genomic RNA (Fig. 8) into virions. By contrast, the cytosolic
portion of Gc was dispensable for recruitment and packaging
of RdRp, N and genome. Particles lacking N are inefficiently
produced (,16% of WT levels) however, we were able to
confirm that they contain genomic RNA. Although N is
capable of non-specifically binding cellular RNA [23],
efficient RVF-VLP release requires genomic RNA. These data
suggest that genomic RNA is recognized specifically, possibly by
Gn, since particles lacking the cytoplasmic portion of Gc
(GcW1) are infectious and efficiently produced (,57% of WT
levels).
Different regions of the Gn cytoplasmic tail are required for
independent interactions with RdRp and N (Fig. 8). The truncated
Gn allele, GnK48, allowed us to define the sequences required for
N and RdRp recruitment. The sequence on the Gn cytosolic tail
required for interaction with N is located within the first 30 amino
acids while that of the RdRp is in the last 40 amino acids. The Gn
domain required for N interaction corresponds to a region that is
highly hydrophobic. The hydrophobic character of this domain is
conserved amongst phleboviruses [12]. Binding of N and RdRp to
Gn can occur independently. This observation may reflect the fact
that there are few copies of RdRp and many copies of N within a
virion. Thus, you would not expect that their binding to Gn would
be mutually dependent.
Figure 6. Viral components required for efficient RVF-VLP release. BSR-T7/5 cells were transfected with genome and all of the structural
proteins (WT), or one or more of the components was replaced with an equivalent amount of empty vector (-RNPCs, -Gn/Gc, -N, -genome, -RdRp).
RNPCs refer to ribonucleoprotein complexes and are defined as genome, N, and RdRp. Transfected cells were analyzed for protein expression by
immunoblot. RVF-VLPs were immune precipitated from the clarified media from transfected cells and analyzed by immunoblot. The numbers below
the immunoblots indicate the ratio of glycoprotein to N signal.
doi:10.1371/journal.pone.0018070.g006










*Value is significantly different from -Gn/-Gc, p,0.001.
doi:10.1371/journal.pone.0018070.t004
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found that the Gn cytoplasmic tail is required for the packaging of
N, but identified a different region as important for this interaction
[53]. The envelope glycoproteins and N of Uukuniemi virus are
divergent from the rest of the phlebovirus genus, which may
explain why our results contrast. Gn interaction with N is unlikely
to be conserved across the five genera within family Bunyaviridae,a s
the envelope glycoproteins and N are not similar. The N (and
RdRp) of the hantaviruses independently localize to perinuclear
membrane structures when expressed alone, suggesting a distinct
mode of assembly [20,54]. For tospoviruses, independent interac-
tions between Gn and Gc with N were discovered, indicating a
possible requirement for both glycoproteins during recruitment
[17].
We found no role for Gc in recruitment of N, genome and
RdRp, however Gc is necessary for optimal Gn expression,
efficient production of RVF-VLPs and possibly, infectivity. Studies
performed on RVFV by Besselaar and Blackburn [55] suggest a
requirement for Gc in virus entry, as they were able to neutralize
virus with antibodies recognizing Gc, either pre- or post- virus
absorption. Computational studies have predicted RVFV Gc to be
a class II viral fusion protein [56], and previous experiments with
other viruses of the Bunyaviridae family support Gc being the main
determinant of cell fusion [57,58,59]. Fusion assays utilizing Gn
and Gc of Bunyamwera virus (Orthobunyavirus genus, Bunyaviridae
family) found that deletions in Gc prevented syncytia formation
[59]. Additional experiments with La Crosse and Tahyna viruses
(Orthobunyavirus genus) identified Gc as a fusion protein using
chimeras, site-directed mutagenesis, and cell-cell-fusion assays
[57,58,59].
Although it has been widely acknowledged that the RdRp is
fundamental to replication and transcription of the RNA virus
genome, other roles for the RVFV RdRp have not been
previously explored. We found that RdRp was not required for
the efficient cellular release of virus or packaging of N and
genome. However, RVF-VLPs that lack RdRp, or express a
catalytically inactive RdRp, cannot be complemented in trans.
Complementing in trans with viral components required for
transcription/replication is not unprecedented. Studies with the
Ebola virus (Ebolavirus genus, Filoviridae family), which is a non-
segmented negative-sense RNA virus, investigated the viral
components necessary for the generation of infectious particles.
The Ebola virus VP30 protein, which is required for replication/
transcription by the RdRp, could be complemented in trans for
restoration of activity in Ebola-VLP-infected target cells [60].
Recently it was discovered that trans expressed influenza virus
(Orthomyxoviridae family) RdRp can replicate viral ribonucleopro-
teins (vRNPs) and become incorporated into progeny vRNPs
[61], however only cis RdRp could transcribe vRNPs. This result
suggests that the cis (packaged) RdRp is somehow different from
the trans (cellular) RdRp [61]. Our complementation studies
suggest that a similar phenomenon may be occurring with
RVFV RdRp, such that a catalytically active RdRp must be
packaged in order for trans expressed RdRp to transcribe a
reporter gene.
We have illuminated roles for each of the viral components in
the assembly, cellular release, and infectivity of RVFV. The
interaction of genome and N with Gn triggers release of virus. Our
Figure 7. Genomic RNA is packaged into RVF-VLPs that lack RdRp. BSR-T7/5 cells were transfected with genome and all of the structural
proteins (WT), or one or more of the components was replaced with an equivalent amount of empty vector (-Gn/Gc, -N, -RdRp, -genome, -Gn and -Gc)
or with plasmids expressing mutant alleles of Gn or Gc (GnK48 or GcW1). At 24 h the media was replaced with fresh media containing benzonase
nuclease. At 48 h the media was removed, clarified and the RVF-VLPs were harvested by ultracentrifugation. The RNA was isolated from the RVF-VLPs
and cDNA was generated with primers that recognize the genomic termini and reverse transcriptase (+RT). Duplicate samples were also run without
reverse transcriptase (-RT). PCR was performed using primers that flank the intergenic region. The numbers on the left of the gel image indicate size
standards.
doi:10.1371/journal.pone.0018070.g007
Table 5. Benzonase treatment reduces background RLuc
activity.





WT 5.78* 0.08 7.57* 0.01
-Gn/-Gc 2.94 0.03 3.49 0.59
-N 2.97 0.00 2.87 0.01
-RdRp 2.93 0.02 2.90 0.09
-Genome 2.93 0.01 2.84 0.00
GnK48 2.96 0.00 3.28 0.45
-Gn 2.97 0.03 3.34 0.50
GcW1 3.48 0.22 4.43* 0.11
-Gc 2.97 0.03 3.08 0.27
*Values are significantly different from the negative control (-Genome), p,0.05.
doi:10.1371/journal.pone.0018070.t005
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PLoS ONE | www.plosone.org 11 March 2011 | Volume 6 | Issue 3 | e18070results illustrate a novel mechanism for the efficient generation of
infectious virus particles. The design and screening of therapeutics
targeting the Gn cytoplasmic tail may offer a novel target for
inhibition of both virus release and packaging of the RdRp and
encapsidated genome.
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